Mayflower Financial Advisors LLC Has $1.09 Million Position in Amgen Inc. (NASDAQ:AMGN)

Mayflower Financial Advisors LLC cut its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 2.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,781 shares of the medical research company’s stock after selling 79 shares during the quarter. Mayflower Financial Advisors LLC’s holdings in Amgen were worth $1,089,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in AMGN. Briaud Financial Planning Inc acquired a new stake in shares of Amgen in the third quarter valued at $26,000. OFI Invest Asset Management bought a new stake in Amgen during the 3rd quarter worth about $26,000. Planned Solutions Inc. acquired a new position in Amgen during the 4th quarter worth $30,000. Providence Capital Advisors LLC bought a new position in Amgen in the 3rd quarter valued at $30,000. Finally, Strategic Investment Solutions Inc. IL bought a new stake in shares of Amgen during the first quarter worth $28,000. 76.50% of the stock is owned by institutional investors.

Amgen Trading Down 0.7 %

Shares of NASDAQ:AMGN opened at $284.32 on Monday. Amgen Inc. has a 52-week low of $211.71 and a 52-week high of $329.72. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. The company has a market capitalization of $152.37 billion, a P/E ratio of 22.76, a price-to-earnings-growth ratio of 2.69 and a beta of 0.58. The company has a 50-day simple moving average of $289.21 and a 200 day simple moving average of $281.03.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The firm had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. During the same quarter in the prior year, the company earned $4.09 earnings per share. The business’s revenue for the quarter was up 19.8% compared to the same quarter last year. Sell-side analysts forecast that Amgen Inc. will post 19.49 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be given a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 3.17%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is 72.06%.

Analyst Ratings Changes

A number of analysts recently commented on the company. The Goldman Sachs Group lifted their price objective on Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a research report on Wednesday, February 7th. UBS Group reduced their price objective on shares of Amgen from $315.00 to $314.00 and set a “neutral” rating on the stock in a research note on Monday, January 29th. Morgan Stanley lowered their target price on shares of Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a report on Wednesday, February 7th. SVB Leerink downgraded Amgen from an “outperform” rating to a “market perform” rating and cut their price target for the company from $324.00 to $318.00 in a research note on Wednesday, February 7th. Finally, Leerink Partnrs cut Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 7th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $295.30.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.